IL137765A0 - Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery - Google Patents

Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Info

Publication number
IL137765A0
IL137765A0 IL13776599A IL13776599A IL137765A0 IL 137765 A0 IL137765 A0 IL 137765A0 IL 13776599 A IL13776599 A IL 13776599A IL 13776599 A IL13776599 A IL 13776599A IL 137765 A0 IL137765 A0 IL 137765A0
Authority
IL
Israel
Prior art keywords
combination
nucleic acid
gene delivery
vasoactive agent
enhanced gene
Prior art date
Application number
IL13776599A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL137765A0 publication Critical patent/IL137765A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
IL13776599A 1998-02-11 1999-02-09 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery IL137765A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2177398A 1998-02-11 1998-02-11
PCT/US1999/002702 WO1999040945A2 (en) 1998-02-11 1999-02-09 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Publications (1)

Publication Number Publication Date
IL137765A0 true IL137765A0 (en) 2001-10-31

Family

ID=21806073

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13776599A IL137765A0 (en) 1998-02-11 1999-02-09 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Country Status (11)

Country Link
EP (2) EP1053025A2 (de)
JP (1) JP2002502885A (de)
KR (1) KR20010015915A (de)
CN (2) CN101186928A (de)
AU (1) AU2663799A (de)
CA (1) CA2320302A1 (de)
EA (1) EA019099B1 (de)
IL (1) IL137765A0 (de)
NZ (1) NZ545047A (de)
WO (1) WO1999040945A2 (de)
ZA (1) ZA991102B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
EP1126869B1 (de) 1998-10-28 2008-09-03 Cornell Research Foundation, Inc. Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
NZ546670A (en) * 1999-11-05 2009-02-28 Univ California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP1294407A2 (de) * 2000-06-30 2003-03-26 Collateral Therapeutics Zweirekombinante enthaltende zusammensetzungen zur gentherapie und verfahren zur herstellung
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
JP5058822B2 (ja) 2005-01-25 2012-10-24 ファイブ プライム セラピューティクス， インコーポレイテッド 心臓の状態を処置するための組成物および方法
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
US8157760B2 (en) 2007-07-18 2012-04-17 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
AU2008350903B2 (en) 2008-02-19 2015-04-02 Sardocor Corp. Compositions for enhanced uptake of viral vectors in the myocardium
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
WO2014160887A2 (en) * 2013-03-28 2014-10-02 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
WO2019089385A1 (en) 2017-11-02 2019-05-09 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US5869230A (en) * 1995-03-30 1999-02-09 Beth Israel Hospital Association Gene transfer into the kidney
WO1999017807A1 (en) * 1997-10-08 1999-04-15 Cobra Therapeutics Ltd. Use of a vasoactive compound in the enhancement of gene delivery
AU9692198A (en) * 1997-10-10 1999-05-03 Kevin J. Donahue Gene delivery compositions and methods

Also Published As

Publication number Publication date
CA2320302A1 (en) 1999-08-19
WO1999040945A2 (en) 1999-08-19
CN101186928A (zh) 2008-05-28
EA200000828A1 (ru) 2001-02-26
ZA991102B (en) 2000-03-31
EP1695719A1 (de) 2006-08-30
AU2663799A (en) 1999-08-30
NZ545047A (en) 2009-05-31
EP1053025A2 (de) 2000-11-22
EA019099B1 (ru) 2014-01-30
CN100350979C (zh) 2007-11-28
KR20010015915A (ko) 2001-02-26
WO1999040945A3 (en) 1999-09-30
CN1301181A (zh) 2001-06-27
JP2002502885A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
IL131486A0 (en) Gene sequencer and methods
AU9692198A (en) Gene delivery compositions and methods
GB9720148D0 (en) Gene silencing materials and methods
EP1019983A4 (de) Verbinder und betriebsverfahren
IL136454A0 (en) Compositions and methods for inducing gene expression
IL137765A0 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
GB9721909D0 (en) Gene delivery vectors and their uses
GB9813310D0 (en) Method of preventing odometer fraud
EP1036159A4 (de) Verfahren für die reinigung von plasmid-dns und von plasmid-dns, die im wesentlichen frei von genomischer dns ist
IL139011A0 (en) Gene coding for helimicine and use thereof
AU8125098A (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
PL345207A1 (en) Gene therapy method
AU4397797A (en) Method of gene introduction
GC0000172A (en) Genomic sequences for protein production and delivery
AU2003204457A1 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
HK1033261A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
PL352387A1 (en) Pharmaceutical composition containing sibutramine and a lipase inhibitor
GB9721376D0 (en) Methods and compositions for enhanced gene delivery
EP1132099A4 (de) Nukleinsäure-transporter und medizinische zusammensetzungen für die gentherapie
AU9449598A (en) Use of a vasoactive compound in the enhancement of gene delivery
AU3895499A (en) Methods and compositions for nucleic acid delivery
AU2497099A (en) Enhancement of delivery of radioimaging and radioprotective agents
GB9718273D0 (en) Gene delivery system
GB9718271D0 (en) Gene delivery system
IL149294A0 (en) Gene mining system and method